Description: Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.
Home Page: www.probi.com
Ideongatan 1A
Lund,
223 70
Sweden
Phone:
46 4 62 86 89 20
Officers
| Name | Title |
|---|---|
| Mr. Tom Ronnlund | Chief Exec. Officer |
| Mr. Henrik Lundkvist | Chief Financial Officer |
| Mr. Andy McShea | Chief Operating Officer |
| Dr. Niklas Larsson Ph.D. | Lead Scientific Affairs |
| Mr. Shane Judge | VP of Global Sales & Marketing |
| Ms. Basudha Bhattarai-Johansson | VP of Human Relations & Sustainability |
| Ms. Veronica Dong | Head of APAC - Singapore |
| Mr. Peter Dybdahl Hede | VP R&D |
| Ms. Magdolna Dimén | Group Controller |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 29.7492 |
| Price-to-Book MRQ: | 1.6107 |
| Price-to-Sales TTM: | 3.5981 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 165 |